Pharmalot

Pharmalot

Biogen is criticized by the National Multiple Sclerosis Society over pricing for its new pill

By Ed Silverman

Pharmalot

Pharmalittle: WHO to advance generic insulins; Trump wants more aggressive foreign pricing index

By Ed Silverman

Pharma

After backlash, Teva will resume supplies of a critical children’s cancer medicine

By Ed Silverman

Pharmalot

Pharmalittle: Most think Trump isn’t doing enough to lower drug costs; a prolonged shortage of heparin is possible

By Ed Silverman

Pharmalot

More Americans can’t afford prescriptions and most think Trump isn’t doing enough to help

By Ed Silverman

Pharmalot

Pharmalittle: Biotechs worry about Democrats’ drug pricing bill; PhRMA criticizes four countries over policies

By Ed Silverman

Pharma

How much? Pharma copay cards are increasing costs for private Canadian insurers

By Ed Silverman

Pharma

Pharmalittle: Can Congress really pass a drug pricing bill this year? Roche closes in on SMA market

By Ed Silverman

Pharma

FDA admits it goofed when granting orphan status to an opioid addiction treatment

By Ed Silverman

Pharmalot

Former Biogen sales rep, who says she was fired for complaining about off-label marketing, is awarded $6 million

By Ed Silverman

Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: New York judge sets next opioid trial; FDA and DEA urged to reschedule an opioid

By Ed Silverman

Pharmalot

Italy is urged not to replace a public health official who pushed for drug pricing transparency

By Ed Silverman

Pharmalot

Another former Sun Pharma sales rep claims she was fired for complaining about off-label marketing

By Ed Silverman

Pharmalot

Pharmalittle: HHS sues Gilead over HIV PrEP pill patents; Purdue and Sacklers shielded from lawsuits until April

By Ed Silverman

Pharmalot

HHS sues Gilead for refusing to reach a licensing deal over patents for HIV prevention pills

By Ed Silverman

Pharmalot

A Takeda vaccine for dengue appears effective, but the story is nuanced

By Ed Silverman

Pharmalot

If Trump were to place tariffs on Swiss drugs, U.S. patients are most likely to get hurt

By Ed Silverman

Pharmalot

Pharmalittle: Trump splits from Pelosi to back Senate drug pricing bill; UPS drones make first delivery for CVS

By Ed Silverman

Pharmalot

What money? The CDC is urged to acknowledge industry funding

By Ed Silverman

Pharmalot

China has become the pharmacy to the world — and a national security risk for the U.S.

By Ed Silverman

Pharmalot

Pharmalittle: Canadian ambassador says imports would not lower U.S. prices; can the Sackler legacy be rebuilt?

By Ed Silverman

Pharmalot

Four state treasurers urge Cardinal Health shareholders to reject a board member

By Ed Silverman

Pharmalot

Pharmalittle: China OKs first home-grown Alzheimer’s drug; White House cool to Pelosi drug pricing bill

By Ed Silverman

Pharmalot

FDA claims Zantac does not form a carcinogen in patients, but says some pills should be recalled

By Ed Silverman

Up and down the ladder: The latest comings and goings

Pharmalittle: Senators propose a new agency to control drug costs; FDA panel backs Amarin fish-oil pill

A drug maker courted controversy when it shut out a family-run rival. Now some patients say the medicine isn’t working

FDA slams Dollar Tree for purchasing drugs from suppliers with checkered safety records

Biogen is criticized by the National Multiple Sclerosis Society over pricing for its new pill

Pharmalittle: WHO to advance generic insulins; Trump wants more aggressive foreign pricing index

After backlash, Teva will resume supplies of a critical children’s cancer medicine

Pharmalittle: Most think Trump isn’t doing enough to lower drug costs; a prolonged shortage of heparin is possible

More Americans can’t afford prescriptions and most think Trump isn’t doing enough to help

Pharmalittle: Biotechs worry about Democrats’ drug pricing bill; PhRMA criticizes four countries over policies

How much? Pharma copay cards are increasing costs for private Canadian insurers

Pharmalittle: Can Congress really pass a drug pricing bill this year? Roche closes in on SMA market

FDA admits it goofed when granting orphan status to an opioid addiction treatment

Former Biogen sales rep, who says she was fired for complaining about off-label marketing, is awarded $6 million

Up and down the ladder: The latest comings and goings

Pharmalittle: New York judge sets next opioid trial; FDA and DEA urged to reschedule an opioid

Italy is urged not to replace a public health official who pushed for drug pricing transparency

Another former Sun Pharma sales rep claims she was fired for complaining about off-label marketing

Pharmalittle: HHS sues Gilead over HIV PrEP pill patents; Purdue and Sacklers shielded from lawsuits until April

HHS sues Gilead for refusing to reach a licensing deal over patents for HIV prevention pills

A Takeda vaccine for dengue appears effective, but the story is nuanced

If Trump were to place tariffs on Swiss drugs, U.S. patients are most likely to get hurt

Pharmalittle: Trump splits from Pelosi to back Senate drug pricing bill; UPS drones make first delivery for CVS

What money? The CDC is urged to acknowledge industry funding

China has become the pharmacy to the world — and a national security risk for the U.S.

Pharmalittle: Canadian ambassador says imports would not lower U.S. prices; can the Sackler legacy be rebuilt?

Four state treasurers urge Cardinal Health shareholders to reject a board member

Pharmalittle: China OKs first home-grown Alzheimer’s drug; White House cool to Pelosi drug pricing bill

FDA claims Zantac does not form a carcinogen in patients, but says some pills should be recalled